Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.94 USD

88.94
1,500,306

+0.65 (0.74%)

Updated Oct 31, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.

Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.

Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?

Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.

5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.

Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?

On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

What's in the Cards for AcelRx (ACRX) This Earnings Season?

AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $66.64, marking a +0.36% move from the previous day.

Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

Key highlights of the past week include earnings update, collaborations and other pipeline news.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

Is a Beat in Store for Repligen (RGEN) This Earnings Season?

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?

We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.

What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

Sweta Killa headshot

Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know

Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

Key highlights of the past week include collaborations and other pipeline updates.

Company News for Jul 16, 2019

Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT

Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

Christopher Vargas headshot

Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play

The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $66.19 in the latest trading session, marking a -1.88% move from the prior day.

Court Ruling Topples Trump Order, No Price Display in TV Ads

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.